Latest news with #JPY200
New Straits Times
20-05-2025
- Business
- New Straits Times
IHH Healthcare unit raises damages sought from Daiichi Sankyo to RM5.7bil
KUALA LUMPUR: IHH Healthcare Bhd's indirect subsidiary, Northern TK Venture Pte Ltd (NTK), has increased the damages it is seeking from Daiichi Sankyo Co Ltd to about JPY200 billion (RM5.7 billion). This marks a tenfold jump from its initial claim of JPY20 billion (RM634 million), the group said in a statement today. In a filing with the Tokyo District Court, NTK applied to amend its ongoing lawsuit, citing a more comprehensive quantification of damages based on expert analysis. The revised claim includes compensation for defamation and reputational harm, and is backed by a report prepared by Osborne Partners, an independent expert appointed by NTK. The lawsuit stems from NTK's claim that Daiichi Sankyo obstructed its attempts to complete an open offer to acquire shares in India-based Fortis Healthcare Ltd (FHL) and its step-down subsidiary, Fortis Malar Hospitals Ltd. NTK said that Daiichi Sankyo's interference caused significant financial losses by preventing the completion of the acquisition and freezing NTK's non-interest-bearing deposit of about JPY60.2 billion, which had been set aside to fund the open offer. "The revised claim now reflects damages under three counterfactual scenarios in which the open offer was completed as scheduled, in the absence of interference from Daiichi Sankyo. "The estimated damages range from INR4.24 billion (RM200 million) to INR109.3 billion (RM5.7 billion), depending on the scenario. The legal dispute dates back to 2018, when NTK was executing a mandatory open offer after acquiring a 31.1 per cent stake in FHL. NTK alleges that Daiichi Sankyo obtained an interim status quo order from India's Supreme Court without notice, halting the offer. Though the court later lifted the order, the open offer could not proceed due to continuing legal threats from Daiichi Sankyo. IHH and NTK maintain that they have no links to the Singh brothers, against whom Daiichi Sankyo has been pursuing separate legal action related to the Ranbaxy acquisition. NTK said it reserves the right to further revise the damages claimed, noting that the alleged interference by Daiichi Sankyo is ongoing. The next hearing in the Tokyo District Court's preparatory proceedings, which are closed to the public, is scheduled for July 11. NTK is the investment vehicle through which IHH holds its interest in FHL and the group considers India a core market alongside Malaysia, Singapore and Türkiye. IHH said it remains committed to expanding its healthcare footprint in India and hopes the legal issues will be resolved swiftly so that it can continue serving the local community.
Yahoo
29-04-2025
- Business
- Yahoo
Daiwa Securities Group Inc (DSECF) (Q4 2024) Earnings Call Highlights: Record Revenues Amidst ...
Release Date: April 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Net operating revenues for the fourth quarter of 2024 increased by 7.9% to JPY174.2 billion. The Wealth Management Division achieved a record high net increase in stock investment trust of JPY174.6 billion. Global Investment Banking posted record net operating revenue and ordinary income growth, driven by large primary deals and higher M&A revenues. The full-year dividend payout ratio reached a record high of 51.1%, with a total payout ratio of 83.6% including share repurchases. Ordinary income for the full year topped JPY200 billion for the first time since 2005, indicating solid results in line with the Medium-Term Management Plan. Ordinary income for the fourth quarter decreased by 19.1% to JPY51 billion. Profit attributable to owners of parent fell by 35.8% to JPY29.9 billion. The Asset Management Division recorded a decline in ordinary income. Overseas operations saw a 25.4% decrease in ordinary income, particularly affected by declines in the Americas. Global Markets experienced a 10.6% drop in net operating revenue, with FICC revenues declining due to high volatility in US interest rates. Warning! GuruFocus has detected 1 Warning Sign with DSECF. Q: Can you provide an overview of Daiwa Securities Group's financial performance for the fourth quarter of 2024? A: Kotaro Yoshida, CFO, explained that net operating revenues for Q4 2024 were JPY174.2 billion, a 7.9% increase from the previous quarter. However, ordinary income decreased by 19.1% to JPY51 billion. The Wealth Management Division saw a record net increase in stock investment trust, while Global Investment Banking posted record net operating revenue and ordinary income growth. Q: How did the Wealth Management Division perform, and what were the key drivers? A: The Wealth Management Division reported net operating revenues of JPY66.4 billion, up 0.6%, and ordinary income of JPY23.1 billion, up 10.1%. Key drivers included increased equity revenues from large primary deals and high levels of distribution commission for investment trusts. The division's asset-based revenues accounted for 47.3% of its net operating revenues. Q: What were the results for the Asset Management Division, particularly in Securities Asset Management? A: Securities Asset Management recorded net operating revenue of JPY14.9 billion, down 1.2%, with ordinary income flat at JPY7 billion. Daiwa Asset Management secured a net inflow of JPY407 billion in publicly offered stock investment trusts, excluding ETFs. Q: How did the Global Markets and Investment Banking Division perform? A: In Global Markets, net operating revenue was JPY36 billion, down 10.6%, with ordinary income decreasing by 30.3%. However, Global Investment Banking saw net operating revenue increase by 1.6% to JPY25.8 billion, and ordinary income rose by 25.5% to JPY6.9 billion, driven by large-scale equity underwriting deals and increased M&A revenues. Q: What strategic initiatives are being prioritized to maximize customer asset value? A: The group is focusing on offering optimal portfolio proposals based on customers' total assets to build an earnings base less susceptible to market fluctuations. This includes continued implementation of total asset consulting and leveraging structural changes in the Japanese economy, such as the shift from savings to investments. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
27-03-2025
- Business
- Yahoo
Japan Extends 50% Cash Rebate Program That Lured Apple TV+'s ‘Monarch' Series
Japan's Ministry of Economy, Trade and Industry has extended its production incentive program through 2025, maintaining its eye-catching 50% cash rebate on qualifying expenditures. The move continues the momentum of Japan being promoted heavily as a filming location, which was evident at last November's Tokyo International Film Festival. More from Variety Seth Rogen Reveals Ridley Scott's Pitch for the 'Monopoly' Movie as 'The Studio' Cast Shares Crazy Hollywood Notes: A Photographer Said, 'You Have a Terrible Body for Clothes' Jessica Chastain, Adam Driver to Star in Apple Series 'The Dealer' 'Severance' Renewed for Season 3 at Apple TV+ The Visual Industry Promotion Organization (VIPO) and Japan Film Commission confirmed on Thursday that the incentive program, which selected 10 international productions in 2024, including Apple TV+'s 'Monarch: Legacy of Monsters Season 2,' will run from March 27, 2025, to Jan. 31, 2026. The incentive applies to half of all qualified spending on production and post-production costs incurred in Japan after a project's official selection. The program caps rebates at JPY1 billion (approximately $6.6 million) per production. To qualify, international projects must meet one of three financial thresholds: direct production costs in Japan exceeding JPY500 million ($3.3 million); total production budget over JPY1 billion ($6.6 million) with at least JPY200 million ($1.3 million) spent directly in Japan; or projects set for distribution in more than 10 countries with minimum direct Japan expenditures of JPY200 million. Applications must come through Japanese production companies or consortiums, as overseas entities cannot apply directly. The program will accept submissions in four rounds throughout 2025, beginning immediately with the first application window running through April 10. The initiative further stipulates that qualifying productions must benefit Japan's domestic content industry through local employment and studio utilization, and that 'scenes shot in Japan are absolutely guaranteed.' Projects must also allow overseas filmmakers to cooperate in promoting filming locations. An exception clause notes that projects failing to meet financial thresholds might still qualify if they 'greatly benefit the Japanese economy and domestic film industry,' with decisions made by an external examination committee. The project completion date must be set within 90 days of work completion or Jan. 31, 2026, whichever comes first, with direct expenses related to film production in Japan eligible for funding. Applications will be processed by VIPO with the Japan Film Commission serving as program coordinator. The program may conclude early if the allocated budget is exhausted before all four application rounds are completed. Best of Variety New Movies Out Now in Theaters: What to See This Week The Best Celebrity Memoirs to Read This Year: From Chelsea Handler to Anthony Hopkins Oscars 2026: First Blind Predictions Including Timothée Chalamet, Emma Stone, 'Wicked: For Good' and More
Yahoo
17-03-2025
- Business
- Yahoo
MEDIROM Healthcare Technologies Inc. Announces New JPY350 Million (Approximately $2.4 Million*) Unsecured Loan Financing
TOKYO, March 17, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the 'Company' or 'MEDIROM'), today announced that it has obtained a new unsecured short-term bank loan in the amount of JPY350 million (approximately $2.4 million*). The Company has used JPY200 million of the loan funds for repayment of indebtedness of MEDIROM Mother Labs Inc., a subsidiary of the Company which is also a guarantor of the new loan, and the Company intends to use the remainder of the loan funds for general working capital, including Mother Bracelet development. The loan bears interest at a rate of 1.875% per year. 'This new loan financing strengthens our financial position, providing additional support for developing Mother Bracelet,' said Koji Eguchi, Chief Executive Officer of MEDIROM. *Convenience translations included in this press release of Japanese yen into U.S. dollars have been made at the exchange rate of JPY148.87 = US$1.00, which was the TTM exchange rate provided by Mizuno Bank on March 17, 2025. Forward-Looking Statements Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about the Company's possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as 'may,' 'will,' 'should,' 'design,' 'target,' 'aim,' 'hope,' 'expect,' 'could,' 'intend,' 'plan,' 'anticipate,' 'estimate,' 'believe,' 'continue,' 'predict,' 'project,' 'potential,' 'goal,' or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include: the Company's ability to achieve its development goals for its business and execute and evolve its growth strategies, priorities and initiatives; the Company's ability to sell certain of its owned salons to investors, and receive management fees from such sold salons, on acceptable terms; changes in Japanese and global economic conditions and financial markets, including their effects on the Company's expansion in Japan and certain overseas markets; the Company's ability to achieve and sustain profitability in its Digital Preventative Healthcare Segment; the fluctuation of foreign exchange rates, which affects the Company's expenses and liabilities payable in foreign currencies; the Company's ability to hire and train a sufficient number of therapists and place them at salons in need of additional staffing; changes in demographic, unemployment, economic, regulatory or weather conditions affecting the Tokyo region of Japan, where the Company's relaxation salon base is geographically concentrated; the Company's ability to maintain and enhance the value of its brands and to enforce and maintain its trademarks and protect its other intellectual property; the financial performance of the Company's franchisees and the Company's limited control with respect to their operations; the Company's ability to raise additional capital on acceptable terms or at all; the Company's level of indebtedness and potential restrictions on the Company under the Company's debt instruments; changes in consumer preferences and the Company's competitive environment; the Company's ability to respond to natural disasters, such as earthquakes and tsunamis, and to global pandemics, such as COVID-19; and the regulatory environment in which the Company operates. More information on these risks and other potential factors that could affect the Company's business, reputation, results of operations, financial condition, and stock price is included in the Company's filings with the SEC, including in the 'Risk Factors' and 'Operating and Financial Review and Prospects' sections of the Company's most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at The Company assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future. About MEDIROM Healthcare Technologies Inc. MEDIROM, a holistic healthcare company, operates 308 (as of January 31, 2025) relaxation salons across Japan, being its leading brand, and provides healthcare services. In 2015, MEDIROM entered the health tech business and launched new healthcare programs using an on-demand training app called 'Lav®', which is developed by the Company. MEDIROM also entered the device business in 2020 and has developed a smart tracker 'MOTHER Bracelet®'. In 2023, MEDIROM launched REMONY, a remote monitoring system for corporate clients, and has received orders from a broad range of industries, including nursing care, transportation, construction, and manufacturing, among others. MEDIROM hopes that its diverse health-related product and service offerings will help it collect and manage healthcare data from users and customers and enable it to become a leader in big data in the healthcare industry. For more information, visit ContactsInvestor Relations Teamir@ in to access your portfolio
